FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1
FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022
https://finance.yahoo.com/news/freeline-announces-fda-clearance-investigational-120000440.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.